Netherlands· NL-f80a3234e4dc
CAMZYOS 5 mg harde capsules
A mavacamten product containing mavacamten, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Mavacamten is registered in 15 of 19 countries.
Countries holding a registration under ATC C01EB24 (mavacamten), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Mavacamten · ATC C01EB24
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mavacamten costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mavacamten · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$118.52
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MAVACAMTEN
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Netherlands (NL)
- ATC code
- C01EB24
- ATC class
- Mavacamten
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1716
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mavacamten in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCAMZYOSBristol-Myers Squibb Pharma EEIG, Dublin
- CanadaCAMZYOSBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandCamzyos
- SpainCAMZYOS 5 MG CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- FinlandCAMZYOSBristol-Myers Squibb Pharma EEIG
- FranceCAMZYOS 5 mg, géluleBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomCamzyos 5mg capsulesBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandCamzyos 5 mg Capsule hardBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Camzyos
- Liechtenstein · Camzyos
- Norway · Camzyos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed876f3d-68ed-4a2e-aed0-3569edfd84dc GET /v1/drugs/ed876f3d-68ed-4a2e-aed0-3569edfd84dc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/camzyos-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Mavacamten",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128591",
"excipients": [
"AMMONIA (E 527)",
"CROSCARMELLOSE NATRIUM (E 468)",
"GELATINE (E 441)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ZWART (E 172)",
"KALIUMHYDROXIDE (E 525)",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"PROPYLEENGLYCOL (E 1520)",
"SCHELLAK (E 904)",
"SILICIUMDIOXIDE, GEHYDRATEERD (E 551)",
"TITAANDIOXIDE (E 171)",
"ZWARTE INKT"
],
"substances": [
"MAVACAMTEN"
],
"leaflet_url": null,
"authorised_at": "2023/06/26",
"procedure_number": "EMEA/H/C/005457",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1716",
"additional_monitoring": "Y"
}See everything about mavacamten.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.